• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·BIMI
Share

BIMI Holdings Inc. Stocks

$ 0Last Updated 31.07.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 1156

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

BIMI International Medical Inc., headquartered in Chongqing, China, is an enterprise engaged in a diverse array of healthcare operations. The company, which was established in 2000 and adopted its current name in June 2021 (formerly BOQI International Medical Inc.), focuses on the supply and sale of medical devices, pharmaceuticals, and other health-related products. Its business activities are structured across four main divisions: wholesale pharmaceuticals, wholesale medical devices, medical services, and retail pharmacies. For its wholesale segment, BIMI distributes a wide range of specialized medical equipment, including Stryker spinal products, Olympus endoscopes, various imported imaging devices, and diagnostic imaging systems. These products are supplied to clients such as drugstores, private clinics, pharmaceutical dealers, and hospitals, particularly within China's Southwest region. The company also facilitates the distribution of a broad spectrum of pharmaceutical products, comprising generic medications, traditional Chinese herbal remedies, biochemical drugs, essential raw ingredients for pharmaceuticals, antibiotics, cardiovascular treatments, and anti-obesity medicines. Through its "Lijiantang Pharmacy" brand, BIMI operates a network of directly-owned retail outlets. These pharmacies offer consumers an extensive selection of items, including prescription and over-the-counter drugs, nutritional supplements, health foods, sundry goods, traditional Chinese medicines, personal and family care products, and medical devices. Beyond product sales, BIMI also delivers medical services within hospital environments and undertakes IT research and development initiatives.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

02.08.2026 02:30

An explosion occurred near a restaurant in central Moscow; there are fatalities

01.08.2026 16:01

Small caps last week: Cathie Wood’s Scribe bet, deals to acquire Forte Bio and CBIZ

01.08.2026 13:01

Apple's Short-Lived Triumph, Non-Banks Battle for Colombia, and a Dinosaur Worth Millions of Dollars

01.08.2026 04:17

Not a White Knight: How the “Savior” of “AI-Nostradamus” Makes Money by Sensing Trouble

01.08.2026 03:08

Trump Ordered New Strikes Against Iran — WSJ

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026